Immune tolerance induction: recombinant vs. human-derived product (Q34117221)

31 July 2017

1 reference

title

Immune tolerance induction: recombinant vs. human-derived product (English)

1 reference

31 July 2017

Berntorp E

1

1 reference

31 July 2017

publication date

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

7

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

109-113

1 reference

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00466.X

10.1046/J.1365-2516.2001.00466.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference